| Title |
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
|
|---|---|
| Published in |
OncoTargets and therapy, November 2013
|
| DOI | 10.2147/ott.s50945 |
| Pubmed ID | |
| Authors |
Jun Liang, Mingyan E, Gang Wu, Lujun Zhao, Xia Li, Xia Xiu, Ning Li, Bo Chen, Zhouguang Hui, Jima Lv, Hui Fang, Yu Tang, Nan Bi, Wenqing Wang, Yirui Zhai, Tao Li, Dongfu Chen, Shuangmei Zou, Ning Lu, Rolando Perez-Rodríguez, Junqi Zheng, Luhua Wang |
| Abstract |
To determine the safety and therapeutic effects of nimotuzumab (h-R3) combined with radiotherapy in esophageal cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 29% |
| Researcher | 6 | 25% |
| Professor > Associate Professor | 4 | 17% |
| Student > Bachelor | 2 | 8% |
| Other | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 1 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 29% |
| Biochemistry, Genetics and Molecular Biology | 3 | 13% |
| Nursing and Health Professions | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Engineering | 2 | 8% |
| Other | 5 | 21% |
| Unknown | 3 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2013.
All research outputs
#20,817,194
of 25,576,801 outputs
Outputs from OncoTargets and therapy
#1,577
of 2,967 outputs
Outputs of similar age
#171,219
of 227,073 outputs
Outputs of similar age from OncoTargets and therapy
#20
of 28 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,073 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.